Advertisement

Are statins effective for simultaneously treating dyslipidemias and hypertension?

      Abstract

      3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are unequivocally useful for lowering cholesterol levels in patients with dyslipidemias characterized by elevations in total and/or low-density lipoprotein cholesterol. The beneficial effects of statins to lower serum cholesterol translate into significant reductions in cardiovascular morbidity and mortality. In addition to lowering cholesterol levels, statins have other biological effects relevant to cardiovascular homeostasis including anti-inflammatory actions and downregulation of angiotensin type 1 receptor expression that contribute to improvements in enodthelial function and arterial compliance. Since enodthelial dysfunction and reduced arterial compliance are important pathophysiological determinants of essential hypertension, these actions of statins raise the possibility that statin therapy may be useful for simultaneously treating dyslipidemias and hypertension. However, it has been unclear whether statins are effective in lowering blood pressure. This controversy stems from a variety of methodological limitations including inadequate sample size, confounding effects of antihypertensive drugs, differences in blood pressure measurement techniques, and differences in patient populations. However, based on published results from both small clinical studies and large randomized clinical trials, statins modestly lower blood pressure in patients with high, but not normal, blood pressure, regardless of cholesterol level.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Koh K.K.
        Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability.
        Cardiovasc Res. 2000; 47: 648-657
        • Nickenig G.
        • Baumer A.T.
        • Temur Y.
        • et al.
        Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men.
        Circulation. 1999; 100: 2131-2134
        • Wassmann S.
        • Laufs U.
        • Baumer A.T.
        • et al.
        HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species.
        Hypertension. 2001; 37: 1450-1457
        • Leibovitz E.
        • Hazanov N.
        • Zimlichman R.
        • Shargorodsky M.
        • Gavish D.
        Treatment with atorvastatin improves small artery compliance in patients with severe hypercholesterolemia.
        Am J Hypertens. 2001; 14: 1096-1098
        • Ferrier K.E.
        • Muhlmann M.H.
        • Baguet J.P.
        • et al.
        Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension.
        J Am Coll Cardiol. 2002; 39: 1020-1025
        • Goode G.K.
        • Miller J.P.
        • Heagerty A.M.
        Hyperlipidaemia, hypertension, and coronary heart disease.
        Lancet. 1995; 354: 362-364
        • Wilkinson I.B.
        • Cockcroft J.R.
        Pravastatin, blood pressure, and stroke.
        Hypertension. 2000; 36: E1-E2
        • Giannattasio C.
        • Mangoni A.A.
        • Failla M.
        • et al.
        Impaired radial artery compliance in normotensive subjects with familial hypercholesterolemia.
        Atherosclerosis. 1996; 124: 249-260
        • Kool M.
        • Lustermans F.
        • Kragten H.
        • et al.
        Does lowering of cholesterol levels influence functional properties of large arteries?.
        Eur J Clin Pharmacol. 1995; 48: 217-223
        • Baldassarre D.
        • Busnach G.
        • Amato M.
        • Pazzucconi F.
        • Sirtori C.R.
        Effect of plasma cholesterol reduction by pravastatin on the functional properties of forearm arteries in hypercholesterolemic patients.
        Nutr Metab Cardiovasc Dis. 1999; 9: 108-117
        • O’Callaghan C.J.
        • Krum H.
        • Conway E.L.
        • et al.
        Short term effects of pravastatin on blood pressure in hypercholesterolaemic hypertensive patients.
        Blood Press. 1994; 3: 404-406
        • Foss O.P.
        • Graff-Iversen S.
        • Istad H.
        • et al.
        Treatment of hypertensive and hypercholesterolaemic patients in general practice. The effect of captopril, atenolol and pravastatin combined with life style intervention.
        Scand J Prim Health Care. 1999; 17: 122-127
        • Rajagopalan S.
        • Zannad F.
        • Radauceanu A.
        • Pitt B.
        A multicenter double-blind randomized controlled trial of a statin + angiotensin receptor blockade combination in patients with hypertension and concomitant hyperlipidemia.
        Circulation. 2004; 110: III-402
        • Ikeda T.
        • Sakurai J.
        • Nakayama D.
        • et al.
        Pravastatin has an additional depressor effect in patients undergoing long-term treatment with antihypertensive drugs.
        Am J Hypertens. 2004; 17: 502-506
        • Borghi C.
        • Prandin M.G.
        • Costa F.V.
        • et al.
        Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia.
        J Cardiovasc Pharmacol. 2000; 35: 549-555
        • Sposito A.C.
        • Mansur A.P.
        • Coelho O.R.
        • Nicolau J.C.
        • Ramires J.A.
        Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril).
        Am J Cardiol. 1999; 83: A8
        • Glorioso N.
        • Troffa C.
        • Filigheddu F.
        • et al.
        Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia.
        Hypertension. 1999; 34: 1281-1286
        • Nickenig G.
        • Jung O.
        • Strehlow K.
        • et al.
        Hypercholesterolemia is associated with enhanced angiotensin AT1-receptor expression.
        Am J Physiol. 1997; 272: H2701-H2707
        • Koh K.K.
        • Quon M.J.
        • Han S.H.
        • et al.
        Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients.
        Circulation. 2004; 110: 3687-3692
        • Koh K.K.
        • Quon M.J.
        • Han S.H.
        • et al.
        Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes.
        Hypertension. 2005; 45: 1088-1093
        • Magen E.
        • Viskoper R.
        • Mishal J.
        • et al.
        Resistant arterial hypertension and hyperlipidemia: atorvastatin, not vitamin C, for blood pressure control.
        Isr Med Assoc J. 2004; 6: 742-746
        • Kanbay M.
        • Yildirir A.
        • Bozbas H.
        • et al.
        Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients.
        Ren Fail. 2005; 27: 297-303
        • Calvo C.
        • Hermida R.
        • Ayala D.
        • et al.
        Atorvastatin reduces ambulatory blood pressure in hyperlipidemic patients with untreated grade 1 essential hypertension.
        Am J Hypertens. 2005; 18: A2
        • Fogari R.
        • Derosa G.
        • Lazzari P.
        • et al.
        Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance.
        Am J Hypertens. 2004; 17: 823-827
        • Straznicky N.E.
        • Howes L.G.
        • Lam W.
        • Louis W.J.
        Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension.
        Am J Cardiol. 1995; 75: 582-586
        • Bak A.A.
        • Huizer J.
        • Leijten P.A.
        • Rila H.
        • Grobbee D.E.
        Diet and pravastatin in moderate hypercholesterolaemia: a randomized trial in 215 middle-aged men free from cardiovascular disease.
        J Intern Med. 1998; 244: 371-378
        • Jenkins D.J.
        • Kendall C.W.
        • Marchie A.
        • et al.
        Effects of a dietary portfolio of cholesterol-lowering foods vs. lovastatin on serum lipids and C-reactive protein.
        JAMA. 2003; 290: 502-510
        • Derosa G.
        • Mugellini A.
        • Ciccarelli L.
        • Fogari R.
        Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet.
        Clin Ther. 2003; 25: 1107-1122
        • Shige H.
        • Dart A.
        • Nestel P.
        Simvastatin improves arterial compliance in the lower limb but not in the aorta.
        Atherosclerosis. 2001; 155: 245-250
        • Lee T.M.
        • Chou T.F.
        • Tsai C.H.
        Association of pravastatin and left ventricular mass in hypercholesterolemic patients: role of 8-iso-prostaglandin f2alpha formation.
        J Cardiovasc Pharmacol. 2002; 40: 868-874
        • Tonolo G.
        • Ciccarese M.
        • Brizzi P.
        • et al.
        Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment.
        Diabetes Care. 1997; 20: 1891-1895
        • Terzoli L.
        • Mircoli L.
        • Raco R.
        • Ferrari A.U.
        Lowering of elevated ambulatory blood pressure by HMG-CoA reductase inhibitors.
        J Cardiovasc Pharmacol. 2005; 46: 310-315
        • Borghi C.
        • Dormi A.
        • Veronesi M.
        • Sangiorgi Z.
        • Gaddi A.
        Brisighella Heart Study Working Party Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study.
        Am Heart J. 2004; 148: 285-292
        • Golomb B.A.
        • Ritchie J.B.
        • Criqui M.H.
        • Dimsdale J.E.
        Statins lower blood pressure: results from the UCSD statin study.
        Circulation. 2004; 110: III-402
        • Poulter N.
        • Sever P.S.
        Do statins lower blood pressure? Evidence from the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA).
        Circulation. 2004; 110: III-402
        • Strazzullo P.
        • Kerry S.M.
        • Barbato A.
        • et al.
        Do statins reduce blood pressure? A meta-analysis of randomized controlled trials.
        Hypertension. 2007; 49: 792-798
        • Rodriguez-Porcel M.
        • Lerman L.O.
        • Herrmann J.
        • et al.
        Hypercholesterolemia and hypertension have synergistic deleterious effects on coronary endothelial function.
        Arterioscler Thromb Vasc Biol. 2003; 23: 885-891
        • Nickenig G.
        • Sachinidis A.
        • Michaelsen F.
        • et al.
        Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells.
        Circulation. 1997; 95: 473-478
        • Koh K.K.
        • Ahn J.Y.
        • Han S.H.
        • et al.
        Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients.
        J Am Coll Cardiol. 2003; 42: 905-910
        • Fukai T.
        • Siegfried M.R.
        • Ushio-Fukai M.
        • Griendling K.K.
        • Harrison D.G.
        Modulation of extracellular superoxide dismutase expression by angiotensin II and hypertension.
        Circ Res. 1999; 85: 23-28
        • Wang C.H.
        • Li S.H.
        • Weisel R.D.
        • et al.
        C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle.
        Circulation. 2003; 107: 1783-1790
        • Delbosc S.
        • Cristol J.P.
        • Descomps B.
        • Mimran A.
        • Jover B.
        Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress.
        Hypertension. 2002; 40: 142-147
        • Weiss D.
        • Kools J.J.
        • Taylor W.R.
        Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice.
        Circulation. 2001; 103: 448-454
        • Li Z.
        • Iwai M.
        • Wu L.
        • et al.
        Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis.
        Hypertension. 2004; 44: 758-763
        • Dahlof B.
        • Sever P.S.
        • Poulter N.R.
        • et al.
        ASCOT investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.
        Lancet. 2005; 366: 895-906
        • Yusuf S.
        • Ostergren J.B.
        • Gerstein H.C.
        • et al.
        Candesartan in heart failure assessment of reduction in mortality and morbidity program investigators. Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure.
        Circulation. 2005; 112: 48-53
        • Koh K.K.
        • Han S.H.
        • Quon M.J.
        Inflammatory markers and the metabolic syndrome: insights from therapeutic interventions.
        J Am Coll Cardiol. 2005; 46: 1978-1985
        • Han S.H.
        • Quon M.J.
        • Koh K.K.
        Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-alpha activators.
        Hypertension. 2005; 46: 1086-1092
        • Kim J.A.
        • Montagnani M.
        • Koh K.K.
        • Quon M.J.
        Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms.
        Circulation. 2006; 113: 1888-1904
        • Han S.H.
        • Quon M.J.
        • Kim J.A.
        • Koh K.K.
        Adiponectin and cardiovascular disease: response to therapeutic interventions.
        J Am Coll Cardiol. 2007; 49: 531-538